"Pharmaceutical headline" Qingdao 12 local cases and 9 million people tested behind.

(2020/10/13) Invest in vs. How profits support the development and commercialization of pandemic therapies; Lilly and Johnson and Johnson announce the latest clinical results for the treatment of Crohn's disease with IL-23 inhibitors; and challenges with two clinical failures in Pfizer's $5 billion heavy-weight drug of the year... (Click on the title to get the original text) Lilly and Johnson and Johnson announce the latest clinical results of IL-23 inhibitors for the treatment of Crohn's disease! The UEG Week 2020 virtual meeting was held from October 11-13, and Lilly and Johnson and Johnson announced the latest results of two phase 2 clinical studies of IL-23 inhibitors mirikizumab and Tremfya for Crohn's disease.
results showed that mirikizumab was treated for 52 weeks, resulting in continuous improvement of symptoms in patients with moderate to severe active CD and a significant reduction in inflammation of the intestinal mucosa, and in patients with moderate to severe active CD, Tremfya showed significant improvement in key clinical and endoscopic outcome indicators compared to placebo, with safety consistent with approved adaptation.
: Crohn's disease can lead to intestinal obstruction, fibrosis and other complications.
Two clinical failures in six months Pfizer's $5 billion heavy-weight drug challenged the company, and Pfizer's nearly $5 billion-a-year sales of the heavy-weight drug Ibrace have again announced a clinical failure, and in May, Pfizer is understood to have announced a clinical failure of the drug.
lilly announced its CDK4/6 clinical advances in June: significantly reducing the risk of recurrence or death from early breast cancer.
Iberance, the world's first CDK4/6 inhibitor to be marketed, received FDA priority approval in 2015 for the initial treatment of ER-/HER2-Post menoptocratic advanced breast cancer, with a market share of nearly 90%.
: Breakthrough therapy is in the eye.
"Eight o'clock" Chinese-style epidemic prevention and control upgrade Qingdao 12 local cases and 9 million people testing the atmosphere from the evening of October 11 began to suddenly tense up, first a sudden cancellation of the Qingdao outbreak release, after 10 p.m., some communities in Qingdao streets, there have been citizens began to line up overnight to carry out nucleic acid testing.
official official announcement, but in various channels began to circulate, Qingdao for the city of more than 9 million people to carry out nucleic acid testing.
: The secret spread of the new coronavirus in Qingdao? New Kangjie investment vs profits How to support pandemic therapy research and development and commercialization of the 2020 new crown pneumonia pandemic swept the world, in general, the world is not fully prepared to respond.
, however, the outbreak has led to changes in investment in infectious diseases, drug development methods and regulatory policies, which could lead to lasting innovation and help mitigate the impact of future pandemics.
: Past pandemic therapies have had limited success.
.